The American Journal of Managed Care1d
Rise of Innovative Therapies for Breast Cancer Treatment
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses advancements in breast cancer treatment, highlighting CDK4/6 inhibitors and ...
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing ...
Novartis Gets CHMP Recommendation for Kisqali in Broader Population
The Committee for Medicinal Products for Human Use adopted a positive opinion for NVS' Kisqali to help reduce the risk of recurrence in people with HR+/HER2- early breast cancer.
European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer
On Friday, Novartis AG (NYSE:NVS) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for ...
Pharmabiz4d
EMA committee recommends marketing approval for Novartis’ Kisqali to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
EMA committee recommends marketing approval for Novartis’ Kisqali to help reduce risk of recurrence in people with HR+/HER2- early breast cancer: Basel Saturday, October 19, 202 ...
The Times of Northwest Indiana1d
Get Healthy: Advances in diagnostics, treatments tackle breast cancer head on
Advances in breast cancer diagnosis and treatment in the last 70 years have considerably increased the survival rate to 18.7 ...
The Financial Express4d
Novartis gets positive CHMP opinion for its breast cancer drug to reduce risk of recurrence
Novartis on Friday announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing ...
Deccan Chronicle4d
Early Detection, Better Survival: The Power of Regular Breast Cancer Screening
The World Health Organization (WHO) reports that approximately 2,000 women are diagnosed with cancer each day. Every day, a ...
PharmTech4d
Several Medicines Recommended by EMA’s CHMP in October
The agency’s CHMP recommended drugs to treatments for hemophilia, two biosimilars for psoriasis, and two flu vaccines at their October meeting.
Le Lézard4d
Actineer, a Joint Venture of ITM and CNL, Begins Actinium-225 Production
Actineer, the joint venture between ITM and Canadian Nuclear Laboratories (CNL) Ltd., has successfully produced Actinium-225 (Ac-225) by irradiating Radium-226 (Ra-226) in a cyclotron. This production ...
pharmaphorum6d
Routine NHS access to Ibrance assured with new NICE guidance
Two other CDK4/6 inhibitors – Novartis' Kisqali (ribociclib) and Eli Lilly's Verzenios (abemaciclib) – have already been approved by NICE for both first- and second-line use in advanced HR+ ...
pharmaphorum3d
A history of: Mapping breast cancer’s journey from past to present
The CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib were approved for HR-positive, HER2-negative disease, blocking cyclin-dependent kinases driving tumour growth. Immunotherapies like ...